Exercise Training for Patients With Poor Leg Circulation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00118560|
Recruitment Status : Completed
First Posted : July 11, 2005
Last Update Posted : March 17, 2011
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 2 Intermittent Claudication||Behavioral: Physical exercise Behavioral: Physical walking||Not Applicable|
Hide Detailed Description
Specific Objectives: 1.Develop an appropriate graded calf exercise test protocol for evaluating perfusion and metabolism during exercise in subjects with peripheral arterial disease (PAD), 2.compare perfusion in gastroc-soleus and tibialis anterior muscles during exercise and recovery from exercise, and to compare metabolism in those muscles during exercise, 3.compare the perfusion during exercise and recovery between groups with and without PAD, and to compare metabolism during exercise between groups with and without PAD, 4.estimate sample sizes and effect sizes for a future clinical trial to determine the efficacy of walking and calf muscle exercise training for improving calf muscle perfusion and metabolism. 5.determine the sensitivity and specificity of the PET exercise test in classifying subjects into groups with or without PAD, and 6. determine the test-retest reliability coefficients of perfusion and metabolic measures.
Two groups of subjects will participate in this study. Group I (n=25 subjects with PAD) will undergo two sets of assessments. Each assessment will consist of completing three questionnaires, two exercise tests, and one PET scan session. Additionally, they will receive one MRI of the legs. Then they will participate in a three-month exercise training intervention consisting of treadmill walking and calf muscle exercise. Finally, they will repeat one set of assessments (listed above with MRI). Group II (n=25 healthy control subjects) will undergo two sets of assessments. Each assessment will consist of three questionnaires, two submaximal exercise tests, one MRI, and one PET scan session (no exercise tests). Additionally they will receive only one MRI. They will not participate in an exercise training intervention.
Experimental Design The project is a pilot study that is both cross-sectional and longitudinal in nature. The initial baseline measurement sessions will allow comparisons of acute perfusion and metabolic physiologic responses between two groups of subjects (with and without PAD). Duplicate testing for each subject will allow assessment of the test-retest reliability of the measurements. The PAD subjects' perfusion and metabolic responses will be assessed again after three months of exercise training (walking and calf muscle exercise). While not a definitive clinical trial of the exercise training intervention, the results should provide estimates of sample and effect sizes to design a more definitive future clinical trial.
Subjects Recruitment and Sampling: Fifty different subjects (N=50) will participate in the project, reflecting the available veteran patient population. The sample will include primarily men, of any age and ethnicity. Twenty-five subjects will have PAD and will be identified and recruited via convenience sampling primarily from the Physical Medicine and Rehabilitation (PM&R) Outpatient Clinic, Diabetes Clinic, and Peripheral Vascular Clinic at the VA West Los Angeles Healthcare Center (VAWLAHC). Other participants may be recruited from other VA Greater Los Angeles Healthcare System locations, specifically the Los Angeles Ambulatory Care Center and the Sepulveda Ambulatory Care Center. Twenty-five "normal" healthy control subjects will be recruited via convenience sampling from well veterans and the general community; the two groups will be matched on gender and age. We plan to enroll 25 subjects with PAD for the three-month exercise training intervention.
Screening and Consent: Research staff will recruit and interview prospective subjects. Prospective subjects who meet all initial inclusion and exclusion criteria will be requested to review and sign the IRB-approved informed consent form and will be enrolled in the project. A physician will physically examine prospective subjects and provide medical clearance prior to participation.
Assessments and Measurements
After screening and consent, the assessment process will progress in four phases:
- Questionnaires to evaluate walking impairment, physical activity, and general health. The information will be used to better characterize the study groups.
- Exercise tolerance testing to demonstrate claudication symptoms in PAD subjects during both treadmill walking and calf muscle exercise and to assess functional changes resulting from training. The control subjects will also perform the exercise tests, but these tests will be submaximal and without pain. The data will be used for comparison to the data from PAD subjects.
- Magnetic Resonance Imaging (MRI) of the legs to measure popliteal artery diameter and document locations of individual muscles and muscle groups.
- PET-exercise testing to measure muscle perfusion and glucose metabolism during calf muscle exercise and recovery.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Perfusion and Metabolism During Exercise in Peripheral Arterial Disease|
|Study Start Date :||June 2005|
|Actual Primary Completion Date :||December 2007|
|Actual Study Completion Date :||December 2007|
treadmill walking and calf exercise
Behavioral: Physical exercise
treadmill walkingBehavioral: Physical walking
calf muscle exercise
- maximal exercise times on treadmill and calf ergometer [ Time Frame: baseline and after 3 months of intervention ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00118560
|United States, California|
|VA Greater Los Angeles Healthcare System, West LA|
|West Los Angeles, California, United States, 90073|
|Principal Investigator:||Stephen F. Figoni||VA Greater Los Angeles Healthcare System, West LA|